Ariana’s XAI Driven Drug Development Platform :
Accelerated Path From Design to Approval
AI Driven Knowledge Integration and Discovery Platform Aiming at Regulatory Strategy
Integrating 100,000s parameters, starting with as few as 10s of patients
RWE Patients Records
Years of experience
We design Precision Medicine Clinical protocols
We can start our process at the pre-clinical
stage or with as few as 10 patients.
We integrate pre-clinical data, data from
past clinical trials when they exist.
Real World Evidence data from our extensive knowledge base in order to identify biomarkers and design a data enriched clinical protocol.
We collect & generate data
Integrate and discover with our XAI Technology
• Optimal dose
• Companion biomarkers and best responders end-points and surrogate endpoints
• Synergistic drug combinations
• Novel indications
Benefiting from over 10 years of close interactions with the FDA,
we transform findings from the KEM® platform into optimal regulatory strategies for accelerated approval
KEM® Technology validated by a large number of partners
Latest Press Releases
Ariana Pharma strengthens management team with appointments of VP Business Development and Chief Financial Officer
Paris, France and Cambridge, MA, USA, July 26th, 2022 – Ariana Pharm...
Ariana Pharma, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.
Paris and Cambridge, MA, June 15th 2022. Ariana Pharma and OmiCure ann...
Anavex Life Sciences and Ariana Pharma present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference
Pushing the promise of AI designed Precision Medicine Parkinson’s Di...